Download PDF
CC BY 4.0 · TH Open 2018; 02(02): e173-e181
DOI: 10.1055/s-0038-1645876
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity

Rolf P. Kreutz
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
2   Department of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Glen Schmeisser
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Andrea Schaffter
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Sri Kanuri
2   Department of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Janelle Owens
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
2   Department of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Benjamin Maatman
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Anjan Sinha
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Elisabeth von der Lohe
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
,
Jeffrey A. Breall
1   Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, United States
› Author Affiliations Funding This study was supported, in part, by the Indiana Clinical and Translational Sciences Institute, funded, in part, by grant number U54-RR025761 (Anantha Shekhar, PI) from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award, as well as the Indiana University Health Values Grant, the Indiana University Health – Indiana University School of Medicine Strategic Research Initiative, and internal funding from the Department of Medicine, Indiana University School of Medicine, Indianapolis. Sample processing and storage was performed in part by the Specimen Storage Facility (SSF) of the Indiana Clinical and Translational Sciences Institute (CTSI) which is supported, in part, by a Clinical and Translational Sciences Award (grant no. UL1TR001108; Anantha Shekhar, PI) and CTSI SSF facility construction was funded in part by grant CO6-RR020128–01 (R.S. Fife, PI; K. Cornetta, Co-I).
Further Information

Publication History

06 December 2017

14 March 2018

Publication Date:
07 May 2018 (online)

   Permissions and Reprints

Abstract

Background High plasma fibrin clot strength (MA) measured by thrombelastography (TEG) is associated with increased risk of cardiac events after percutaneous coronary interventions (PCIs). Factor XIIIa (FXIIIa) cross-links soluble fibrin, shortens clot formation time (TEG-K), and increases final clot strength (MA).

Methods We analyzed platelet-poor plasma from patients with previous PCI. Kaolin-activated TEG (R, K, MA) in citrate platelet-poor plasma and FXIIIa were measured (n = 257). Combined primary endpoint was defined as recurrent myocardial infarction (MI) or cardiovascular death (CVD). Relationship of FXIIIa and TEG measurements on cardiac risk was explored.

Results FXIIIa correlated with TEG-MA (p = 0.002) and inversely with TEG-K (p < 0.001). High MA (≥35.35 mm; p = 0.001), low K (<1.15 min; p = 0.038), and elevated FXIIIa (≥83.51%; p = 0.011) were associated with increased risk of CVD or MI. Inclusion of FXIIIa activity and low TEG-K in risk scores did not improve risk prediction as compared with high TEG-MA alone.

Conclusion FXIIIa is associated with higher plasma TEG-MA and low TEG-K. High FXIIIa activity is associated with a modest increase in cardiovascular risk after PCI, but is less sensitive and specific than TEG-MA. Addition of FXIIIa does not provide additional risk stratification beyond risk associated with high fibrin clot strength phenotype measured by TEG.

Keywords

thrombelastography - fibrin - factor XIII - percutaneous coronary intervention - myocardial infarction
 

  • References

  • 1 Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997; 130 (04) 401-411
    CrossrefPubMedGoogle Scholar
  • 2 Nielsen VG, Gurley Jr WQ, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004; 99 (01) 120-123
    CrossrefPubMedGoogle Scholar
  • 3 Bhavnani SP, Parakh K, Atreja A. , et al. 2017 roadmap for innovation-ACC health policy statement on healthcare transformation in the era of digital health, big data, and precision health: a report of the American College of Cardiology Task Force on Health Policy Statements and Systems of Care. J Am Coll Cardiol 2017; 70 (21) 2696-2718
    CrossrefPubMedGoogle Scholar
  • 4 Degoma EM, Rivera G, Lilly SM, Usman MH, Mohler III ER. Personalized vascular medicine: individualizing drug therapy. Vasc Med 2011; 16 (05) 391-404
    CrossrefPubMedGoogle Scholar
  • 5 Eikelboom JW, Connolly SJ, Bosch J. , et al; COMPASS Investigators. Rivaroxaban with or without Aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
    CrossrefPubMedGoogle Scholar
  • 6 Bitar A, Kreutz RP. Role of thrombelastography (TEG) in risk assessment and guidance of antithrombotic therapy in patients with coronary artery disease. Drug Dev Res 2013; 74: 533-540
    CrossrefPubMedGoogle Scholar
  • 7 Lu D, Owens J, Kreutz RP. Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. Thromb Res 2013; 132 (02) e94-e98
    CrossrefPubMedGoogle Scholar
  • 8 McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100 (06) 1576-1583
    CrossrefPubMedGoogle Scholar
  • 9 Gurbel PA, Bliden KP, Guyer K. , et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46 (10) 1820-1826
    CrossrefPubMedGoogle Scholar
  • 10 Kreutz RP, Schmeisser G, Maatman B. , et al. Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention. Thromb Haemost 2017; 117 (02) 426-428
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001; 104 (06) 467-474
    CrossrefPubMedGoogle Scholar
  • 12 Hethershaw EL, Cilia La Corte AL, Duval C. , et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12 (02) 197-205
    CrossrefPubMedGoogle Scholar
  • 13 Byrnes Jr JR, Wolberg AS. Newly-recognized roles of factor XIII in thrombosis. Semin Thromb Hemost 2016; 42 (04) 445-454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Schroeder V, Kohler HP. Factor XIII: structure and function. Semin Thromb Hemost 2016; 42 (04) 422-428
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Thygesen K, Alpert JS, Jaffe AS. , et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation 2012; 126 (16) 2020-2035
    CrossrefPubMedGoogle Scholar
  • 16 Cutlip DE, Windecker S, Mehran R. , et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115 (17) 2344-2351
    CrossrefPubMedGoogle Scholar
  • 17 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 18 Gurbel PA, Bliden KP, Navickas IA. , et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010; 160 (02) 346-354
    CrossrefPubMedGoogle Scholar
  • 19 Gurbel PA, Bliden KP, Cohen E. , et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis 2008; 19 (04) 268-275
    CrossrefPubMedGoogle Scholar
  • 20 Bridge KI, Philippou H, Ariëns R. Clot properties and cardiovascular disease. Thromb Haemost 2014; 112 (05) 901-908
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Zacho M, Rafiq S, Kelbæk H. , et al. Hypercoagulability in relation to coronary artery bypass graft patency and clinical outcome. Scand Cardiovasc J 2013; 47 (02) 104-108
    CrossrefPubMedGoogle Scholar
  • 22 Rafiq S, Johansson PI, Ostrowski SR, Stissing T, Steinbrüchel DA. Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome. Eur J Cardiothorac Surg 2012; 41 (03) 550-555
    CrossrefPubMedGoogle Scholar
  • 23 Lau YC, Xiong Q, Shantsila E, Lip GY, Blann AD. Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. J Thromb Thrombolysis 2016; 42 (04) 535-544
    CrossrefPubMedGoogle Scholar
  • 24 Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood 2014; 124 (26) 3982-3990
    CrossrefPubMedGoogle Scholar
  • 25 Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost 2011; 9 (01) 9-20
    CrossrefPubMedGoogle Scholar
  • 26 Byrnes Jr JR, Duval C, Wang Y. , et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 2015; 126 (16) 1940-1948
    CrossrefPubMedGoogle Scholar
  • 27 Jayo A, Conde I, Lastres P, Jiménez-Yuste V, González-Manchón C. New insights into the expression and role of platelet factor XIII-A. J Thromb Haemost 2009; 7 (07) 1184-1191
    CrossrefPubMedGoogle Scholar
  • 28 Kreutz RP, Owens J, Lu D. , et al. Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel. Platelets 2015; 26 (04) 358-363
    CrossrefPubMedGoogle Scholar
  • 29 Schlimp CJ, Solomon C, Ranucci M, Hochleitner G, Redl H, Schöchl H. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry. Anesth Analg 2014; 118 (02) 269-276
    CrossrefPubMedGoogle Scholar
  • 30 Stone GW, Witzenbichler B, Weisz G. , et al; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382 (9892): 614-623
    CrossrefPubMedGoogle Scholar
  • 31 Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion 2013; 53 (05) 1120-1131
    CrossrefPubMedGoogle Scholar